Do Wall Street Analysts Like Catalent Stock?

Catalent, Inc. (CTLT), with a market cap of $10.8 billion and based in New Jersey, is a leading global provider specializing in advanced delivery technologies, development, and manufacturing solutions for drugs, including biologics like protein, cell, and gene therapies, as well as consumer health products.

Shares of this healthcare company have outperformed the broader market in the last year. While CTLT has surged 34% over this time frame, the broader S&P 500 Index ($SPX) has rallied by 28.1%. In 2024, the stock soared 32.3%, compared to SPX’s 17.3% return on a YTD basis.